# ProQR Therapeutics (PRQR) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/PRQR
## Company Profile
- Ticker: PRQR
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Netherlands and listed in the U
- Tags: Ophthalmology
## Stock Data
- Close: 1.86 USD
- Market cap: 154882949.97 USD
- Last updated: 2026-08-12
## Business Overview
### RNA Editing Company
ProQR Therapeutics develops RNA-editing medicines using its Axiomer platform.
### Axiomer Technology
Axiomer recruits endogenous ADAR enzymes to make precise single-base changes in RNA without permanently altering DNA.
### AX-0810
AX-0810 targets NTCP and is being developed initially for biliary atresia, with early clinical work measuring target engagement in healthy volunteers.
### Pipeline Expansion
Additional programs include AX-0811 and IDUA-targeting AX-0422, supported by internal and partnered discovery capabilities.
## Why The Stock Is Moving

The latest monitored company update is “ProQR Announces Second Quarter 2026 Operating and Financial Results.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Full Phase 1 dataset for AX-0810 at a medical or scientific conference later in 2026.
- Initial Phase 1 data for AX-0811 by the end of 2026.
- Initiation and initial data from the biliary-atresia investigator study in the first half of 2027.
- Initial patient data for AX-0422 in MPS I Hurler syndrome in the first half of 2027.
- Advancement of AX-2911 into clinical development in the first half of 2027.

## Recent News
- 2026-08-13 11:00 EST — [ProQR Announces Second Quarter 2026 Operating and Financial Results](https://biopharmsignal.com/news/PRQR/proqr-announces-second-quarter-2026-operating-and-financial-results-5d1c30aa) — Source: ProQR Therapeutics
- 2026-06-25 10:35 EST — [ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement](https://biopharmsignal.com/news/PRQR/proqr-prices-50-0-million-underwritten-registered-direct-offering-and-concurrent-67a09dc9) — Source: ProQR Therapeutics
- 2026-06-25 10:25 EST — [ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform](https://biopharmsignal.com/news/PRQR/proqr-announces-positive-phase-1-target-engagement-data-for-ax-0810-establishing-ceb340ef) — Source: ProQR Therapeutics
- 2026-05-12 11:00 EST — [ProQR Announces First Quarter 2026 Operating and Financial Results](https://biopharmsignal.com/news/PRQR/proqr-announces-first-quarter-2026-operating-and-financial-results-dda57c8a) — Source: ProQR Therapeutics
- 2026-05-11 12:00 EST — [ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform](https://biopharmsignal.com/news/PRQR/proqr-announces-multiple-upcoming-scientific-conference-presentations-highlighti-883b5faf) — Source: ProQR Therapeutics